Palovarotene is a selective retinoic acid receptor gamma (RARγ) agonist that is being studied as a potential treatment for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that causes bones in the body to form in soft tissues, leading to progressive physical disability. It is thought to work by preventing the formation of new bone, allowing existing bone to be broken down by the body. Palovarotene has been shown to be effective in animal models of FOP, and is currently in clinical trials to evaluate its safety and efficacy in humans.
Palovarotene, sold under the brand name Sohonos, is a medication specifically designed to target a rare disease called Fibrodysplasia Ossificans Progressiva (FOP) [Wikipedia, Palovarotene]. Here's a breakdown of its key points:
- Condition: Treats heterotopic ossification (HO), a condition where bone forms abnormally in soft tissues, specifically in the context of FOP.
- Mechanism: It works by selectively targeting a molecule called retinoic acid receptor gamma (RARγ). By activating RARγ, palovarotene disrupts two signalling pathways (BMP and SMAD) that are involved in bone formation. This ultimately helps prevent the abnormal bone growth in FOP.
- Dosage: Taken orally (as capsules).